HDAC9 and cancer: To date, several preclinical studies of parthenolide in combination with other drugs such as DMAPT, HDAC inhibitors, and anthracyclines have been conducted; they showed that PN increases cancer cell apoptosis and reduces drug resistance, despite the poor bioavailability of this compound [222,223].